A385 mean age for the entire obese sub-sample was 54.8 ( ( 15.5), compared to 45,8 ( to 45,8 ( 45,8 ( 18,4) for the non-obese participants. 40.4% of the obese participants suffered from at least one comorbid disease such as hypertension, diabetes, hyperlipidaemia, compared to a much lower 21.1% for the remaining sample. The unadjusted SF-12 scores for obese and non-obese participants were: PCS 44.9 ( 44.9 ( 12.0) and 50.5 ( and 50.5 ( 50.5 ( 9.8) (OBJECTIVES: Obesity is a major risk factor for a number of chronic diseases, including diabetes, cardiovascular diseases and cancer. Obesity and its comorbidities significantly depress patients quality of life. The aim of this study was to estimate the impact of obesity on quality of life in Polish population. METHODS: The 20-item WRSM (Weight-Related Symptom Measure) and EQ-5D (EuroQol) questionnaires as well VAS (visual analogue scale) were used to asses Qol in obese patients (BMI 30 kg/m 2 ), treated in National Food and Nutrition Institute in Warsaw. We used EQ-5D Polish TTO-value set to estimate health uitlity. EQ-5D utility and VAS were compared to previously published Polish population norms (age specific for EQ-5D or age and sex specific for VAS). Data are presented as mean (SD). RESULTS: Data on 68 obese patients are available with 18 (26.5%) being severely obese (BMI 40). The mean age of observed population was 52.6 (12.6) years and mean BMI was calculated at 37.2 (6.6) kg/m 2 . The mean state of health recorded on the visual analogue scale was 72.6 (15.3). The mean utility value (EQ-index) was estimated at 0.868 (0.154). The mean WRSM value was estimated at 16.9 (16.6). The mean utility value was comparable to age specific data (based on population with BMI 26.2) -0.899; p 0.282, however mean VAS was significantly (p 0.003) lower to this estimated based on age and sex specific norms (78.5 in a given population). There were weak correlations between BMI and either EQ-index (R 2 0.11), VAS (R 2 0.14) or WRSM (R 2 0.15). Population of patients with severe obesity (BMI 40) had significantly lower EQ-index and VAS and significantly higher WRSM compared to the rest of obese population (p 0.044; 0.046 and 0.016 respectively). CONCLUSIONS: Obesity has significant negative impact on patients quality of life. There is no straightforward correlation between BMI and QoL indices.
PSY52 DEFI A FRENCH PREVALENCE STUDY OF FIBROMYALGIA (FM), HEALTH RELATED QUALITY OF LIFE : SF36
Servant D 1 , Perrot S 2 , Ravaud P 3 , Vicaut E 4 , Kosa M 5 , Pichot L 5 1 Clinique Michel Fontan, Lille, France, 2 Hôpital Hôtel Dieu Paris (France), Paris, France, 3 Groupe Hospitalier Bichat Paris (France), Paris, France, 4 Hôpital Fernand Widal Paris (France), Paris, France, 5 PFIZER FRANCE, Paris, France OBJECTIVES: This part of DEFI study aimed at assessing Qol in a FM population whose diagnosis was suspected or clinically confirmed. METHODS: In a French crosssectional study, 6000 subjects were screened by phone using the French validated London Fibromyalgia Epidemiological study Screening Questionnaire (LFES-SQ) which was positive for 232 of them (LFES-SQ ). On this population 145 accepted to fill in SF36 and were proposed a rheumatologist consultation : 49 refused but filled in questionnaires, 20/96 who accepted the consultation and questionnaires (CS ) were diagnosed as FM (FM ) on the ACR criteria. RESULTS: Normalized SF36 subscales mean values of LFES-SQ subjects are as follow: Physical Functioning (PF) 42.3 10.4, Role Physical (RP) 36,8 9.4, Bodily Pain (BP) 42,5 7.1, General Health (GH) 39,9 9.6, Vitality (VT) 41.3 6.6, Social Functioning (SF) 43.5 9,4, Role Emotional (RE) 43,7 9,4 , Mental Health (MH) 36,8 7.4. Physical component score (PCS) was 42.4 8.4 while mental component score (MCS) was 40.0 9.5. No significant differences were observed between CS and CS-subjects. In contrast, comparisons between the FM and FM-subjects showed in most cases significant differences : PF 37.7 8.1 vs 44.6 9.4 (p 0.003), RP 33.6 5.4 vs 36.9 10.0 (p 0.053), BP 39.6 6.0 vs 43.5 6.1 (p 0.011), GH 33.2 8.2 vs 42.3 9.0 (p 0.0001), VT 39. 
PSY53 PELVIC PAIN IN ENDOMETRIOSIS: EFFECT OF PAINKILLERS OR SPORT TO ALLEVIATE SYMPTOMS
Koppán Á, Hámori J, Vránics I, Garai J, Kriszbacher I, Bódis J, Rébék-Nagy G, Boncz I, Koppán M University of Pécs, Pécs, Hungary OBJECTIVES: To assess potential individual factors influencing quality of life and pain scores of patients suffering from histologically confirmed endometriosis. Study using a questionnaire among patients of reproductive age undergoing laparoscopy among patients of reproductive age undergoing laparoscopy of reproductive age undergoing laparoscopy undergoing laparoscopy with a presumed diagnosis of endometriosis. METHODS: Details of fertility, previous treatments and quality of life, sexual activity, as well as linear pain scores for several symptoms, were recorded. Details of intraoperative findings were also collected and only those data were used where endometriosis was intraoperatively and histologically proven. A questionnaire before surgery gathered information from women on the A questionnaire before surgery gathered information from women on the following groups of variables: age, marital status, education, reproductive and medical history including previous pregnancies and parity, knowledge of accompanying pelvic disorders, regular sport activity, as well as general quality of life estimates including self-image. Pelvic pain was scored using a visual analogue scale. RESULTS: Eighty-one patients complaining about persistent pelvic pain were later intraoperatively and histologically proven to have endometriosis. Thirty-one of them (38.2%) reported regular sport as part of their daily life schedule while 50 of them (61,8%) performed no physical activity at all. Fourteen patients among regular exercisers and 33 patients among those without physical activity reported the effectiveness of painkillers for pelvic pain, corresponding to 45.1% and 66% of these subgroups, respectively (difference statistically significant, p 0.05). CONCLUSIONS: Based on our results, we can conclude, that taking painkillers might be less effective among endometriosis patients performing regular daily sport activities, and, thus it might impose them to an unnecessary burden of possible side effects.
PSY54

COST-EFFECTIVENESS OF ENZYME REPLACEMENT THERAPY FOR GAUCHER'S DISEASE IN THE URAL ADMINISTRATION DISTRICT OF RUSSIA FEDERATION
Zhukovskaya EV 1 , Ustugova AM 2 , Spichak II 3 , Zub NV 4 1 Medical Academy, Chelyabinsk, Russia, 2 Health Ministry of Chelyabinsk Region, Chelyabinsk, Russia, 3 Regional Children's Hospita, Chelyabinsk, Russia, 4 Regional Children Hospital, Chelyabinsk, Russia OBJECTIVES: To estimate effectiveness of enzyme replacement therapy (ERT) in the treatment of symptomatic Gaucher's disease in the Ural's cohort in Russia. METHODS: Information sources were the databases of regional registries in 3 big towns of Ural administration District of Russian Federation: Ekaterinburg, Perm, Chelyabinsk, updated January 2009. Most of the parameters were derived from the published literature. Doses of Cerezymeare varies from 1200 un. till 2000 un. ERT was assumed to restore patients to full health in the base case. Regional cohort include 21 patients, middle age 23 years old. Quality of life was tested by Short Form 36 (SF-36). RESULTS: Seventy percent of the patients were diagnosed in childhood and have 1 type Gaucher Disease. The clinic characteristics were typical. Bone abnormalities were the most serious. Data on this topic were obtained from the primary medical sources. The mean cost of the disease calculated about a120,000. The cost per patient varied considerably by dose. Nonetheless , quality of life indicate that patients treated with ERT continue to have reduced health-related quality of life 0.5 compared with the general population 0.75. And as much more younger seriously sick patients started ERT-quality of life index could be higher. The social efficacy of ERT equivalent extra number of life years, in this cohort it's about 13.7 years.Economic evaluations were found, all of which calculated a very high cost per quality-adjusted life-year (QALY). Incremental cost per QALY incremental cost-effectiveness ratio (ICER) in the base case a210,000. CONCLUSIONS: Although ERT for treating the 'average' Gaucher's disease patient supported by the national program for orphan diseases, despite of it great expense. However, although doing so will be of clinical interest, it is questionable whether, within the current pricing environment, such research would have any substantive impact on policy decisions.
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IMPACT OF THE NEW RECOMMENDATIONS IN THE USE OF PROTHROMBIN COMPLEX CONCENTRATES AND VITAMIN K ANTAGONISTS IN FRANCE: ILLUSTRATION OF THE GUIDELINES RESPECT IN HOSPITAL AND ITS ECONOMIC CONSEQUENCES
Bernard M, Mimoun G, Arnaud P, Peytavin G Bichat-Claude Bernard hospital, Paris, Ile de france, France OBJECTIVES: New recommendations were elaborated in April 2008 in France regarding overdoses, situations of hemorrhagic risk and bleeding accidents occurring in patients treated with vitamin-K antagonists (VKA). Considering the necessity for hospitals to guarantee the good therapeutic use of drugs to obtain reimbursement by public health insurance, and with the significant increase of prescriptions in 2008, a systematic follow-up of correspondence between prothrombin complex concentrates use (PCC, Kaskadil®) and current guidelines was analyzed. METHODS: A prospective study of patients treated with PCC in 2008 was conducted. Data collected included demographic, therapeutic (indication, dosage), biological (INR, PT), clinical (bleeding, surgery . . .) and pharmacoeconomic parameters. Results are expressed as median and interquartile range . RESULTS: Ninety-one patients (41 men, median age: 76 years) received PCC, namely 78.4% compared to 2007, for a total cost of a81 K ( 73%). Analysis of prescriptions reveals that indications corresponded to the marketing authorisation (MA): 36% of bleeding under VKA, 30% of urgent surgery or invasive procedure and 29% of overdose (INR 5). Fluindione was the mainly prescribed VKA (77%). Median values of INR were 4 (2.9-6.9) and PT 33.5% (24-54%). Median doses of PCC were in accordance with MA and recommendations:
